Inactive Instrument

All News DENI THERPAR Nasdaq

Equities

All News

Unlock all the news: Be the first to know and act before the market!

Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell Small Cap Comp Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2500 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2000 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000E Value Index	01/07	CI
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	14/06	CI
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06	AQ
Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise	03/06	MT
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06	GL
Denali Therapeutics Inc. Announces FDA Selects DNL126 for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06	CI
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating	08/05	MT
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating	08/05	MT
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	08/05	GL
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial	01/05	GL
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial	01/05	CI
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04	AQ
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	09/04	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04	MT
Denali Therapeutics Files Prospectus for Secondary Offering	23/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News DENI THERPAR Nasdaq

Equities

All News

Filters